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Abstract
Multimorbidity, which is defined as the co-occurrence of two or more chronic conditions, has moved onto 
the priority agenda for many health policymakers and healthcare providers. Patients with multimorbidity are 
high utilizers of healthcare resources and are some of the most costly and difficult-to-treat patients in Europe. 
 Preventing and improving the way multimorbidity is managed is now a key priority for many countries, and 
work is at last underway to develop more sustainable models of care. Unfortunately, this effort is being hampered 
by a lack of basic knowledge about the aetiology, epidemiology, and risk factors for multimorbidity, and the effi-
cacy and cost-effectiveness of different interventions. The European Commission recognizes the need for reform 
in this area and has committed to raising awareness of multimorbidity, encouraging innovation, optimizing 
the use of existing resources, and coordinating the efforts of different stakeholders across the European Union. 
Many countries have now incorporated multimorbidity into their own healthcare strategies and are working to 
strengthen their prevention efforts and develop more integrated models of care. Although there is some evidence 
that integrated care for people with multimorbidity can create efficiency gains and improve health outcomes, 
the evidence is limited, and may only be applicable to high-income countries with relatively strong and well-
resourced health systems. In low- to middle-income countries, which are facing the double burden of infectious 
and chronic diseases, integration of care will require capacity building, better quality services, and a stronger 
evidence base. 
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strain on many health systems. People with multimor-
bidity have complex care needs and are some of the most 
costly and challenging patients to manage. Although it 
has at last been recognized that more sustainable mod-
els of care for multimorbidity should be introduced as 
a matter of urgency, policymakers and healthcare pro-
viders need good quality evidence on which to build 
the case for change. But how much do we really know 
about multimorbidity? Do we know enough to help us 
prioritize patients, intervene most appropriately, and 
apply the best and most cost-effective models of care? 
In this article, this important question is addressed from 
four different perspectives: the clinician, the European 
Introduction
The number of people affected by multiple chronic dis-
eases (multimorbidity) is increasing dramatically around 
the world, and caring for them has placed considerable 
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Commission, the health policymaker and the health 
economist.
Understanding the epidemiology, risk factors, 
and consequences of multimorbidity 
We have been working hard to improve the manage-
ment of chronic diseases for many decades, with major 
investments made across the board. Today, however, as 
budgets tighten and every expenditure must be scruti-
nized and defended, the focus is turning towards those 
patients generating the highest costs, but experiencing 
the least benefit from healthcare systems. In a nutshell, 
these are the patients with multiple chronic conditions – 
those with “multimorbidity”. 
Multimorbidity is defined as the co-occurrence of 
two or more chronic conditions [1,2] and has been esti-
mated to affect up to 95% of the primary care population 
aged 65 years and older [3]. Although the prevalence of 
multimorbidity increases with age, it is not exclusively 
a condition affecting the elderly, with many studies 
reporting high rates of multimorbidity amongst work-
ing-age populations (Figure 1) [3]. 
Risk factors for multimorbidity have not been well 
studied. Ageing is the most consistent and potent risk 
factor, and it has recently been proposed that multimor-
bidity may be the result of a multisystem loss of reserve 
and function that leads to a low-grade proinflammatory 
state, multiple hormonal dysregulation, and an increased 
susceptibility to chronic diseases [4,5]. Women and 
those with a lower socioeconomic status appear espe-
cially prone to developing multimorbidity [3], although 
the reasons for this are not yet clear. A recent 10-year 
follow-up study conducted in Finland reported that 
predisposing factors for multimorbidity amongst a dis-
ease-free population were smoking, physical inactivity 
and high body mass index, with hypertension and low 
level of education as additional risk factors reported 
in men [6]. Other studies have found a clear associa-
tion between obesity and multimorbidity [7–10], with 
one study demonstrating that accumulating unhealthy 
lifestyle factors progressively increases the risk of 
 multimorbidity [9].
The consequences of multimorbidity are wide-ranging 
and severe. People with multimorbidity die prematurely 
[11]; they have more frequent hospital admissions and 
longer hospital stays [12]; and they see a large number of 
different medical specialists during a typical year [12]. A 
recent analysis of the direct costs of multimorbidity in 
the United States Veterans Affairs Health Care System 
reported that, of the 5% of the highest-cost patients in 
the system (who accounted for 47% of total healthcare 
costs), approximately two-thirds had multiple chronic 
conditions [13]. 
Multimorbidity also profoundly affects an individual’s 
well being, quality of life, and ability to function nor-
mally [14]. In studies conducted up to 2003, an inverse 
relationship between multimorbidity and overall qual-
ity of life was reported; however, the closest association 
observed was the effect of multimorbidity on physical 
functioning [14]. Reduced physical functioning may lead 
to the development of depression and other affective dis-
orders, adding to the medication burden associated with 
multimorbidity. Patients with multimorbidity struggle 
to managing the multiple medications prescribed to 
them [15], leading to difficulties with treatment adher-
ence, and further reduction in quality of life.
Despite the increasing numbers of patients with mul-
timorbidity, clinical practice guidelines and delivery of 
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Figure 1 Prevalence of multimorbidity by age group: overall (a) and by sex (b) in primary care studies identified in a systematic review of the 
literature. Reproduced from Violan C et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of 
observational studies. PLoS One 2014;9(7):e102149 [3].
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care are still primarily built around single diseases, which 
can have many undesirable effects [16,17]. To deliver 
better and more cost-effective care for our patients 
with multimorbidity, we must shift the paradigm from 
vertical monomorbid approaches to horizontal multi-
morbid ones. Our services need to be reorganized to 
deliver individualized and more structured care, better 
care co-ordination and management, enhanced multi-
disciplinary teamwork, and greater support for patient 
education and self-management – optimizing the use 
of 21st century technology solutions wherever we can. 
Clinical practice guidelines will need to be developed 
that are relevant to the needs of patients with multi-
morbidity, and which will require complex treatment 
decisions to be made in the absence of high-quality or 
direct evidence [17]. 
During this time of considerable change, we will have 
to accept that extra investment will initially be required 
while our focus moves onto primary prevention, the 
management of younger patients with multimorbidity, 
and the development of healthcare systems that are bet-
ter equipped to meet the needs of older patients. It is 
believed that, within 20 or so years, this investment will 
reap rewards, bringing tangible benefits to individuals, 
populations, and healthcare systems.
Improving our understanding of 
multimorbidity: what is the European 
Commission doing?
It has been estimated that at least 50 million people in 
the European Union (EU) have multimorbidity, and 
this number is expected to increase further as the popu-
lation ages [18]. Multimorbidity reduces life expectancy, 
affects the individual’s quality of life and ability to work, 
increases the risk of hospitalization, and leads to exces-
sive use of other healthcare resources [19]. Ultimately, 
multimorbidity impacts the sustainability of health and 
social care systems. 
Health systems have traditionally been disease-
oriented, focusing on curing or managing individual 
acute and chronic conditions. Although most patients 
with multimorbidity are affected by common condi-
tions – such as hypertension, ischaemic heart disease, 
and diabetes, none of which are rare and all of which 
are individually treatable – the problem originates from 
the failure to adequately accommodate the interplay 
between them. Indeed, the disease-oriented approach 
does not work for the patient with multimorbidity, 
resulting in fragmented, inefficient, and ineffective care. 
If we are to improve the resilience and sustainability of 
health systems, a paradigm shift will be required towards 
a more patient-centred model that addresses the needs 
of theses individuals in a more holistic way, focusing 
on multidisciplinary, integrated, and coordinated care. 
Achieving this will require innovation and reform at all 
levels of the political and healthcare systems. 
The European Commission is ideally placed to 
contribute to these reforms by raising awareness of 
multimorbidity, encouraging innovation, optimizing 
the use of existing resources, and bringing together 
and coordinating the efforts and expertise of different 
stakeholders. Multimorbidity has been identified as a 
key issue by the European Innovation Partnership on 
Active and Healthy Ageing, which was established in 
2011 to improve the health of our ageing population 
[20]. The Partnership’s three priority areas for action 
are: (1) prevention, screening, and early diagnosis; (2) 
care and cure; and (3) active ageing and independent 
living. Action Groups have been established to research, 
compile, and disseminate good practices throughout 
Europe in several areas, including prescription and 
adherence to medical plans and integrated care – both 
of which address important aspects of the management 
of multimorbidity. In its first review of good practices 
across Europe [21], the Action Group on Prescription 
and Adherence to Medical Plans identified a major issue 
with polypharmacy and poor medication adherence 
amongst patients with multimorbidity, highlighting the 
increased risk of adverse events and hospitalization asso-
ciated with inappropriate prescribing. Preliminary work 
has also been completed to identify successful inter-
ventions, such as medication review and reconciliation 
aimed at reducing polypharmacy, and to identify inap-
propriate prescriptions in patients with multimorbidity, 
and these are summarized in the Group’s 2013 report 
[21]. In addition, as a result of the collaborative work 
dynamics established in the Action Group, a follow-up 
collaboration has been established through the Stimu-
lating Improvement Management of Polypharmacy and 
Adherence in The Elderly (SIMPATHY) project, an 
EU-funded activity aiming to stimulate, promote, and 
support innovation across the EU in the management of 
appropriate polypharmacy and adherence in the elderly, 
in order to contribute to efficient and sustainable health-
care systems [22]. The Action Group on Integrated Care 
has focused on practical tools to support local service 
delivery, mapping innovative solutions for the manage-
ment of chronic diseases to improve the quality and 
sustainability of services [23].
The European Commission has also funded the 
Innovating Care for People with Multiple Chronic 
Conditions in Europe ( ICARE4EU) project [24], under 
the framework of its Health Programme 2008–2013, to 
provide insight into current practices of integrated care 
for people with multimorbidity in European  countries 
[18] (see also Albreht et al. [25]). The project has so 
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far analysed integrated care activities in 31 European 
 countries, with 101 innovative approaches identified to 
date [26].
More recently, the European Commission has ini-
tiated the Joint Action on Chronic Diseases and 
Promoting Healthy Ageing Across the Life Cycle 
( JA-CHRODIS) [27], bringing together over 60 collab-
orating partners from 26 member states. These partners 
are working together to identify, validate, exchange, 
and disseminate good practice across the EU, with a 
focus on health promotion and primary prevention of 
chronic disease. In recognition of the failings of current 
models to adequately address multimorbidity, a work 
package on multimorbidity has been established within 
the  JA-CHRODIS, with the aim of advising on the best 
possible patient-centred care model for patients with 
multimorbidity, taking into account outcomes, cost-
effectiveness, applicability, and replicability. 
Considering multimorbidity in a broader context, 
one of the Commission’s highest current priorities is 
the issue of health system performance assessment. In 
September 2014, the Council Working Party on Public 
Health at Senior Level adopted the Terms of Reference 
from an Expert Group on Health Systems Perfor-
mance Assessment (HSPA), which provides member 
states with a forum for exchange of experiences on the 
use of HSPA at a national level. A subgroup on inte-
grated care has been established that will contribute to 
designing a framework for performance assessment of 
integrated care, paving the way to supporting national 
policymakers by identifying tools and methodologies 
for developing HSPAs. This will eventually serve as a 
basis on which to determine whether the integrated care 
interventions we are designing are performing well for 
patients with multimorbidity.
The findings from many of these initiatives were dis-
cussed at a recent European Commission conference 
entitled, “Which priorities for a European policy on multimorbid-
ity?”, held in Brussels on October 27, 2015 [28]. The aim 
of the conference was to share experiences and practices in 
the management of multimorbidity, to learn from inno-
vative healthcare approaches, and to explore how we can 
overcome the barriers to a common framework in multi-
morbidity. The conference represented a milestone in the 
development of EU public policies on multimorbidity, cre-
ating a common engagement across stakeholders aimed at 
addressing multimorbidity at a European level. The stake-
holders at the meeting identified priorities in order to move 
towards building a common framework on multimorbid-
ity. These priorities are summarized in Table 1 [28]. 
The European Commission is committed to address-
ing all aspects of multimorbidity and to developing 
policies and guidance that are evidence-based and rel-
evant across the EU and within its member states. 
National policymakers are encouraged to use the work 
of the European Commission to help inform their own 
policies and to contribute to the cross-fertilization of 
ideas and exchange of best practices in this field. 
Table 1 Priorities to be addressed in order to build a common European framework on multimorbidity [28].
Research  Healthcare organization  Cost-effectiveness and financing  Patient engagement
•	 Development	of	a	more	precise	
and operational definition
•	 Epidemiology,	risk	factors	and	
determinants
•	 Polypharmacy,	drug–drug	
interactions
•	 Observational	studies
•	 Clinical	trials	(inclusion	of	
patients with multimorbidity)
•	 Clinical	practices/interventions:	
more evidence needed
•	 Risk	stratification	to	target	
subgroups
 •	 Evidence-based	care	model	to	be	
adapted to national and regional 
specificities
•	 Implementation	of	integrated	care	
pathways
•	 Integration	and	interoperability	of	
ICT and eHealth systems for the 
exchange of data across services and 
professionals
•	 Adaptation	of	health	professionals’	
education curriculum with a more 
patient-centred and multidisciplinary 
approach and training on shared 
decision-making
•	 Introduction	of	change	management	
interventions to change current 
mind-set, including a multi-
stakeholder approach
•	 Development	of	decision-making	
tools and risk stratification tools to 
tailor interventions to patients’ needs
•	 Definition	of	standards	to	translate	
evidence into practice
 •	 Encouraging	synergies	between	
patient-centred and budget-
centred measures
•	 Broadening	the	current	type	of	
outcomes (e.g. to include well-
being measures)
•	 Definition	of	targets	and	expected	
outcomes to develop financing 
schemes
•	 More	evidence	needed	on	
cost-effectiveness and on the 
effectiveness of long-term 
interventions (e.g. prevention 
interventions)
•	 Comparable	and	uniform	ways/
methods to measure cost-
effectiveness
•	 Raising	awareness	of	the	burden	
of multimorbidity through 
economic data
 •	 Promotion	of	citizen	
engagement beyond patient 
engagement
•	 Tailored	patient	
information and education 
to raise awareness and 
increase responsibility in 
self care management
•	 Higher	patient	involvement	
in the decision-making 
process
•	 Patient	involvement	in	
clinical studies and trials
•	 Promotion	of	prevention	
initiatives
•	 Support	for	patients	with	
multimorbidity to stay 
active at work
eHealth, electronic health; ICT, information and communications technologies.
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Making a national commitment to preventing 
multimorbidity: the Slovenian experience
Slovenia is a central European country bordering Italy, 
Austria, Croatia, and Hungary, with a population of just 
over 2 million. The country was formally a constituent 
part of Yugoslavia, but declared independence in June 
1991, joining the EU in May 2004. Slovenia has a demo-
cratic political system with a parliamentary form of state 
power. The country has enjoyed continuous economic 
growth since 1992, and is now ranked among the most 
developed countries in the world in terms of its economy. 
The health system of Slovenia has undergone a major 
transformation since the country achieved independ-
ence. Fundamental reforms aimed at modernizing 
the health system were implemented in 1992, with 
the introduction of compulsory health insurance, an 
approval process for the provision of private healthcare, 
the introduction of co-payments for healthcare services, 
and the reintroduction of professional associations [29]. 
Today, as a result of these and many other subsequent 
reforms, Slovenia has a modern, health insurance-based 
system that is built around country-wide primary care 
providers that aim to offer integrated healthcare deliv-
ered within the local community [29].
A rapidly ageing population
As in many other central and eastern European coun-
tries, the population of Slovenia is ageing rapidly. The 
birth rate has decreased from 15.7 per 1,000 population 
in 1980 to 10.3 per 1,000 population in 2014, while 
at the same time, life expectancy has increased to just 
below the EU average of 80.6 years (in 2013) [30]. As a 
result, since the early 1990s, the elderly population (aged 
65 years and older) has increased by approximately 60%, 
and by 2014, elderly people accounted for 17.2% of the 
total population [31]. Unsurprisingly, the prevalence of 
multimorbidity in Slovenia is also increasing [32].
Addressing multimorbidity through prevention  
and coordinated care
The rapidly ageing population poses a major challenge 
to the health system of Slovenia, and significant work is 
underway to meet the increasing demands placed on the 
system by the rising incidence of chronic conditions and 
multimorbidity, and by the increasing rates of obesity 
and other risk factors within our population.
The most recent national healthcare plan, highlighted 
the prevention and management of chronic diseases as key 
areas for strategic development, with health enhancement 
programmes recommended to tackle common risk fac-
tors, such as the harmful use of alcohol, tobacco, unhealthy 
diets, and physical inactivity, and poor mental health [33]. 
A new proposal of the health plan has recently been 
adopted by the  Government and is now pending adoption 
by the Parliament. In this proposal, the ageing population 
and related multimorbidity and non-communicable dis-
eases (NCDs) are recognized as the main challenges for 
the sustainability of the health system. Some of the prior-
ity areas of action in optimizing healthcare include the 
integration of services; upgrading primary healthcare and 
mental health services; empowering patients; investing in 
preventive services; and all of the society approach to risk 
factors. 
An analysis of the system, in cooperation with the 
European Observatory for Health Systems and  Policies 
and the World Health Organization, has now been com-
pleted. The analysis has shown that Slovenia has a robust 
primary healthcare that offers a good foundation to 
address the changing health and healthcare needs of the 
population; but it faces the challenge of fragmentation of 
service organization and delivery.
In addition, when looking for appropriate solutions 
to better control NCDs, we have learned a lot from the 
care of patients with diabetes, a common and potentially 
preventable chronic condition that requires demanding 
and complex care. By bringing together experts from 
different specialties and patients – and learning from 
both – we have been able to develop a National Diabetes 
Strategy by 2020 that puts patients firmly at the cen-
tre, and builds on the principles of empowering patients, 
fostering partnership, coordinating care across different 
providers, both vertically and horizontally, and ensur-
ing ongoing follow-up through a coordinating group 
and action plans [34]. In developing the plan, our goals 
were to reduce the prevalence of diabetes, ensure its 
early detection, and reduce the incidence and impact of 
complications – goals that could readily be applied to the 
management of most long-term conditions.
To tackle multimorbidity, in particular, we have focussed 
our planning on several key areas. Firstly, we recognized 
that both social deprivation and mental health problems 
increase the risk of multimorbidity [35], so we are com-
mitted to ensuring that social and healthcare providers 
work more closely to address these issues more effectively. 
Patients with mental health problems receive treatment 
from a broad range of professionals, including psychia-
trists and home nurses, who serve to connect the patient 
with hospital, community, and social care providers, and 
to monitor the patient’s condition and medications [36]. 
In addition to receiving both acute and long-term treat-
ments, patients with mental health conditions engage 
in group therapies and disease-prevention programmes, 
receive occupational therapy, and participate in pro-
grammes that promote independence and social inclusion 
and reintegration. 
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Secondly, since the prevalence of multimorbidity con-
tinues to rise across our population and within younger 
age groups, we are investing further to strengthen our 
prevention programmes. Health promotion and educa-
tion have been at the heart of our endeavours to reduce 
the burden of NCDs and multimorbidity since 2002, 
and The National Public Health Institute, with its 
 Centre for the Management of Prevention Programmes 
and for Health Promotion designs, prepares, and moni-
tors national prevention and screening programmes, 
including those targeted towards lifestyle interventions. 
Health promotion and education programmes are also 
delivered at the primary care level by nurses and other 
healthcare professionals in health education centres 
within the community health centres.
In 2011, we launched the concept of “model practices” 
aimed at enhancing the role of primary care practices 
in the prevention of chronic conditions and encourag-
ing lifestyle changes. These practices are supported by 
registered nurses who work part-time in family medi-
cine	practices	to	educate	patients	with	chronic	diseases/
multimorbidity on risk-factor management and self-
care. Our goal is to increase the time available for these 
activities within each model practice and to expand the 
service across all primary care providers. Model practices 
play a key role in navigating patients between specialists, 
thereby reducing duplication and omission, and improv-
ing service efficiency. 
Finally, we are addressing the needs of vulnerable 
population groups with multiple risk factors and chronic 
conditions who do not attend services offered in pri-
mary healthcare. There is evidence that multimorbidity 
is more prevalent in people from lower socioeconomic 
groups [35]. By strengthening community nursing in 
primary care and introducing protocols for cooperation 
between primary and secondary care teams and with 
social services, we aim for better integration of services, 
including social care services, in this regard.
We have witnessed unparalleled change in the  Slovenian 
healthcare system over the past 25 years, and the system 
will continue to evolve as new challenges emerge and we 
refocus our efforts where they are needed most. There 
are many hurdles to overcome before we are delivering 
effective and cost-effective care to our patients with mul-
tiple chronic conditions; however, we are committed to 
achieving this and are moving in the right direction. 
How cost-effective is integrated care for chronic 
conditions? How much do we really know?
The recent announcement by the United Nations of their 
sustainable development goals for the 2030 Agenda for Sus-
tainable Development has propelled universal healthcare 
and NCDs into the international development spotlight 
[37]. This has the potential to shift the health develop-
ment agenda away from one that is disease-specific, 
with vertical funding and approaches to implementa-
tion, to more integrated, systems-based approaches to 
achieve “health for all”. This is a welcome development. 
However, while integration of services seems logical for 
high-capacity health systems, as a global community, we 
know very little about the cost-effectiveness of integrated 
care approaches, and even less about the cost-effectiveness 
of treating multimorbidity, or the benefits of integrated 
care for these patients. Emerging evidence from a rare, 
randomized controlled study conducted in the United 
States, revealed that transitioning from a disease-focused 
model to one of collaborative care delivery was indeed 
cost-effective, and helped to eliminate cost redundancies 
when managing patients with multiple chronic conditions 
[38]. This primary-care-based study used a randomized 
design to evaluate the ability of a systematic care man-
agement programme aimed at improving depression, 
haemoglobin A
1C
 , systolic blood pressure, and low-
density lipoprotein cholesterol in patients with poorly 
controlled diabetes mellitus, coronary heart disease (or 
both), and comorbid depression. Patients were random-
ized to receive usual care or an enhanced collaborative 
care intervention in which nurse care managers worked 
with patients and primary care physicians to provide treat-
ment of multiple-disease risk factors [38]. By 24 months 
post-randomization, compared with the control group, 
the intervention patients had experienced an average of 
114 additional depression-free days, and an estimated 
0.335 additional quality-adjusted life-years. Average out-
patient cost savings of US $594 per patient over 2 years 
were reported. This study provides encouraging evidence 
that integrated care for people with multimorbidity may 
be cost-effective, and the results of other ongoing stud-
ies (e.g. the MPI_AGE European Project [39]) may shed 
further light on this issue.
While high-income countries are working to redefine 
how existing health systems can address multimorbid-
ity most efficiently, low- and middle-income countries 
are facing additional challenges. For these countries, the 
battle to combat infectious diseases is ongoing, against a 
backdrop of weak health systems and vertically focused 
donor approaches. Unlike in high-income countries, 
the burden of multimorbidity in countries with low 
or middle incomes includes the immediate and long-
term consequences of infectious diseases. In South 
Africa, for example, the prevalence of human immu-
nodeficiency virus in adults is close to 30%, leading to 
widespread premature ageing and the increased risk of 
cardiovascular disease associated with some antiretrovi-
ral treatments. Overweight and obesity are prevalent and 
largely uncontrolled in both the general population and 
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amongst those infected with human immunodeficiency 
virus, and hypertension rates are also rising. Training for 
community healthcare workers to recognize and treat 
the symptoms of, and risk factors for, chronic condi-
tions is suboptimal, and most healthcare professionals 
are already working at full capacity. A similar picture 
emerges from other regions of Africa and other low-
income countries.
In situations such as these, where poverty and a low 
capacity coexist, questions remain over the value of inte-
grating infectious and chronic disease care. A systematic 
review of the impact of integrating primary healthcare 
services in low- and middle-income countries found 
that, while there was some evidence that adding extra 
services or creating links between existing services 
improved the delivery of healthcare, there was no evi-
dence that better integration improved health status 
[40]. Indeed, in some cases, integration led to deteriora-
tion in service delivery.
For well-financed, high-quality health systems that 
have the capacity, knowledge, and ability to share that 
knowledge, it seems likely that integrating care for peo-
ple with multimorbidity will create efficiency gains and 
improve health outcomes. In contrast, for developing 
countries facing the double burden of infectious and 
chronic diseases, integration of services will need to be 
matched by capacity assessments and capacity building, 
better quality services, and a stronger body of evidence. 
Unfortunately, it seems the world may not yet be ready 
for a global approach to improving the management of 
multimorbidity, and the goal of sustainable health sys-
tems and health for all, as set forth by the sustainable 
development goals, are a long way off.
Summary and conclusions
Considering the major impact of multimorbidity on 
individuals and healthcare systems, surprisingly little 
is known about the phenomenon. Information gaps 
exist in almost all critical areas, including understand-
ing its aetiology, epidemiology, and risk factors, how 
best to prevent and manage it, and how to optimize 
care delivery. The European Commission has identi-
fied multimorbidity as a key priority and is working 
to raise awareness, encourage innovation, optimize the 
use of existing resources, and coordinate the efforts of 
all stakeholders working in the field. Many EU coun-
tries have already prioritized multimorbidity in their 
national health strategies, and work is underway to 
improve its management. Integrated care approaches to 
managing patients with multimorbidity may prove to 
be cost-effective, but the evidence is currently limited, 
and these approaches may not be universally applicable. 
The bottom line is that we are now in the uncom-
fortable position of knowing we urgently need to do 
something about multimorbidity, but without sufficient 
basic  information to guide us, we may not know exactly 
what that is.
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